Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Who owns the stock
Who owns 60 Degrees Pharmaceuticals (SXTP) stock
8 funds reported 60 Degrees Pharmaceuticals (SXTP) shares in their latest 13F filings, worth $615K in all. The largest holder is Kathmere Capital Management, LLC ($467K). Last quarter 4 funds added to their stakes and 5 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Kathmere Capital Management, LLC | 265,100 | $467K | increase | 2026-06-30 |
| Citadel Advisors LLC | 22,362 | $39K | new | 2026-06-30 |
| XTX Topco | 17,639 | $31K | new | 2026-06-30 |
| Kovack Advisors | 15,000 | $26K | new | 2026-06-30 |
| Geode Capital Management, LLC | 14,551 | $26K | decrease | 2026-06-30 |
| UBS Group AG | 13,592 | $24K | decrease | 2026-06-30 |
| Barclays | 1,475 | $2K | increase | 2026-09-30 |
| Osaic Holdings | 25 | $44 | unchanged | 2026-06-30 |
60 Degrees Pharmaceuticals' latest quarter
60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year), net loss $2.3M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most SXTP stock?
By the latest 13F filings: Kathmere Capital Management, LLC ($467K); Citadel Advisors LLC ($39K); XTX Topco ($31K); Kovack Advisors ($26K); Geode Capital Management, LLC ($26K).
What is the short interest in SXTP?
135,408 shares were sold short at the 2026-10-15 settlement, 1.54% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.